Nervgen Pharma Corp.

NGEN chart

Nervgen Pharma Corp. news

• NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

  Yahoo Finance · Oct 12, 7:15 AM EDT

• NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments

  Yahoo Finance · Sep 25, 4:30 PM EDT

• NervGen to Host Inaugural R&D Day on September 30, 2026

  Yahoo Finance · Sep 9, 7:30 AM EDT

• NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

  Yahoo Finance · Aug 13, 7:30 AM EDT

• NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

  Yahoo Finance · May 26, 7:15 AM EDT

• NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

  Yahoo Finance · May 21, 11:27 PM EDT

• NervGen Announces Proposed Public Offering of Securities

  Yahoo Finance · May 21, 4:01 PM EDT

• NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

  Yahoo Finance · May 18, 7:15 AM EDT

• NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

  Yahoo Finance · Apr 27, 7:30 AM EDT

• NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

  Yahoo Finance · Apr 13, 7:45 AM EDT

• NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

  Yahoo Finance · Apr 7, 7:30 AM EDT

• NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

  Yahoo Finance · Mar 31, 7:45 AM EDT

Nervgen Pharma Corp. key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-KFORM 6-K2026-09-25
• 6-KFORM 6-K2026-09-24
• 6-KFORM 6-K2026-08-13
• 6-KFORM 6-K2026-07-02
• 6-KFORM 6-K2026-06-01
• 6-KFORM 6-K2026-05-26
• 6-KFORM 6-K2026-05-22
• 6-KFORM 6-K2026-05-18
• 6-KFORM 6-K2026-05-15
• 6-KFORM 6-K2026-04-27
• 6-KFORM 6-K2026-03-13
• 6-KFORM 6-K2026-02-13

About Nervgen Pharma Corp.

Ticker

NGEN (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Vancouver

Fiscal year end

December 31

SEC CIK

1751912

Frequently asked questions